A HIV injection has become available that reduces the risk of infection by 99.9 percent.

The FDA has approved a generic version of lenacavapir, a treatment that significantly reduces the risk of HIV transmission. This new injectable medication, requiring administration only twice a year, offers a more accessible alternative to daily oral tablets. Originally developed by Gilead Sciences, lenacavapir was prohibitively expensive at over $14,000 per dose. However, Dr. Reddy’s Laboratories and Unitaid have created a generic version priced at $20 per dose. This approval is expected to expedite access in 120 low- and middle-income countries, potentially reaching 20 million people at risk of HIV infection.